K
37.10
0.09 (0.24%)
| Previous Close | 37.01 |
| Open | 37.02 |
| Volume | 394,366 |
| Avg. Volume (3M) | 718,209 |
| Market Cap | 2,749,395,456 |
| Price / Earnings (TTM) | 742.00 |
| Price / Sales | 5.03 |
| Price / Book | 5.35 |
| 52 Weeks Range | |
| Earnings Date | 29 Jul 2025 |
| Profit Margin | -3.52% |
| Operating Margin (TTM) | 9.63% |
| Diluted EPS (TTM) | -0.240 |
| Quarterly Revenue Growth (YOY) | 72.50% |
| Total Debt/Equity (MRQ) | 2.17% |
| Current Ratio (MRQ) | 3.66 |
| Operating Cash Flow (TTM) | 44.03 M |
| Levered Free Cash Flow (TTM) | 25.15 M |
| Return on Assets (TTM) | -1.77% |
| Return on Equity (TTM) | -3.81% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Bullish | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Bullish | Mixed | |
| Stock | Kiniksa Pharmaceuticals, Ltd. | Bullish | Bullish |
AIStockmoo Score
0.3
| Analyst Consensus | 3.0 |
| Insider Activity | -5.0 |
| Price Volatility | -3.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | 0.30 |
|
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Growth |
| % Held by Insiders | 3.80% |
| % Held by Institutions | 97.31% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 54.00 (Jefferies, 45.55%) | Buy |
| Median | 48.00 (29.38%) | |
| Low | 42.00 (Wells Fargo, 13.21%) | Buy |
| Average | 48.00 (29.38%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 29.59 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Jefferies | 29 Jul 2025 | 54.00 (45.55%) | Buy | 30.37 |
| Wells Fargo | 09 Jul 2025 | 42.00 (13.21%) | Buy | 28.80 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| MEGNA MICHAEL R | - | 34.88 | -11,375 | -403,135 |
| MOAT ROSS | - | 34.28 | -481 | -16,489 |
| PAOLINI JOHN F. | - | 34.28 | -835 | -28,624 |
| PATEL SANJ K | - | 34.28 | -3,177 | -108,908 |
| RAGOSA MARK | - | 34.28 | -900 | -30,852 |
| TESSARI EBEN | - | 34.88 | -16,041 | -567,995 |
| Aggregate Net Quantity | -32,809 | |||
| Aggregate Net Value ($) | -1,156,002 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 34.58 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| MEGNA MICHAEL R | Officer | 03 Sep 2025 | Automatic sell (-) | 11,000 | 35.48 | 390,280 |
| MEGNA MICHAEL R | Officer | 03 Sep 2025 | Option execute | 11,000 | - | - |
| TESSARI EBEN | Officer | 03 Sep 2025 | Automatic sell (-) | 15,091 | 35.48 | 535,429 |
| TESSARI EBEN | Officer | 03 Sep 2025 | Option execute | 15,091 | - | - |
| PATEL SANJ K | Officer | 02 Sep 2025 | Disposed (-) | 3,177 | 34.28 | 108,908 |
| PATEL SANJ K | Officer | 02 Sep 2025 | Option execute | 6,569 | - | - |
| RAGOSA MARK | Officer | 02 Sep 2025 | Disposed (-) | 900 | 34.28 | 30,852 |
| RAGOSA MARK | Officer | 02 Sep 2025 | Option execute | 1,861 | - | - |
| PAOLINI JOHN F. | Officer | 02 Sep 2025 | Disposed (-) | 835 | 34.28 | 28,624 |
| PAOLINI JOHN F. | Officer | 02 Sep 2025 | Option execute | 1,725 | - | - |
| MOAT ROSS | Officer | 02 Sep 2025 | Disposed (-) | 481 | 34.28 | 16,489 |
| MOAT ROSS | Officer | 02 Sep 2025 | Option execute | 994 | - | - |
| MEGNA MICHAEL R | Officer | 02 Sep 2025 | Disposed (-) | 375 | 34.28 | 12,855 |
| MEGNA MICHAEL R | Officer | 02 Sep 2025 | Option execute | 774 | - | - |
| TESSARI EBEN | Officer | 02 Sep 2025 | Disposed (-) | 950 | 34.28 | 32,566 |
| TESSARI EBEN | Officer | 02 Sep 2025 | Option execute | 1,964 | - | - |
| Show more | ||||||
| Date | Type | Details |
|---|---|---|
| 28 Aug 2025 | Announcement | Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences |
| 29 Jul 2025 | Announcement | Kiniksa Pharmaceuticals Reports Second Quarter 2025 Financial Results and Recent Portfolio Execution |
| 24 Jul 2025 | Announcement | Kiniksa Pharmaceuticals to Report Second Quarter 2025 Financial Results on July 29, 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |